北京大学学报(医学版) ›› 2018, Vol. 50 ›› Issue (4): 640-644. doi: 10.3969/j.issn.1671-167X.2018.04.012

• 论著 • 上一篇    下一篇

肺腺癌新分类与表皮生长因子受体基因突变之间的关系

张晓东1,刘德若2△   

  1. (1.北京大学国际医院胸外科, 北京102206; 2.中日友好医院胸外科, 北京100029)
  • 出版日期:2018-08-18 发布日期:2018-08-18
  • 通讯作者: 刘德若 E-mail:deruoliu@sina.vip.com

Correlation between the new lung adenocarcinoma classification and epidermal growth factor receptor mutation

ZHANG Xiao-dong1, LIU De-ruo2△   

  1. (1.Department of Thoracic Surgery, Peking University International Hospital, Beijing 102206, China; 2.Department of Thoracic Surgery, China-Japan Friendship Hospital, Beijing 100029, China)
  • Online:2018-08-18 Published:2018-08-18
  • Contact: LIU De-ruo E-mail:deruoliu@sina.vip.com

摘要: 目的:探讨肺腺癌新分类与表皮生长因子受体(epidermal growth factor receptor,EGFR)基因突变之间的关系。方法:共纳入中日友好医院2010年3月至2014年12月经手术肺切除术后且病理证实为浸润性肺腺癌患者94例,对其进行EGFR基因突变检测;入组患者均按照2011 年国际肺癌研究学会(Intemational Association for the Study of Lung Cancer,IASLC)、美国胸科学会(American Thoracic Society,ATS)和欧洲呼吸学会(European Respiratory Society,ERS)分类方法进行肺腺癌亚型分类,分析肺腺癌新分类与EGFR基因突变之间的关系;采用SPSS 20.0统计软件卡方检验分析,P<0.05为差异有统计学意义。结果:入组的94例肺腺癌患者,男、女患者均为47例;年龄24~79岁,中位年龄61岁,60岁及以上48例,60岁以下46例;既往或现在吸烟者34例,不吸烟者60例。根据病理分期,Ⅰ期患者34例,Ⅱ期患者17例,Ⅲ期24例,Ⅳ期19例。EGFR基因外显子19突变例数22,外显子20突变例数2,外显子21突变例数26,外显子10和21同时突变例数1,入组患者EGFR基因总突变率为54.3%(51/94),其中腺泡状为主型肺腺癌EGFR突变例数24例,伏壁状为主型肺腺癌14例,乳头状为主型肺腺癌与实体状为主型肺腺癌均为5例,微乳头状为主型肺腺癌3例,黏液腺癌为0;腺泡状为主型肺腺癌较非腺泡状为主型肺腺癌EGFR突变率高,但差异无统计学意义(66.7% vs. 46.6%, P=0.057);实体状为主型肺腺癌较非实体状为主型肺腺癌EGFR突变率低,差异有统计学意义(26.3% vs. 61.3%, P=0.005);黏液腺癌较非黏液腺癌EGFR基因突变率低,差异有统计学意义(0 vs. 57.3%, P=0.018)。结论:不同的病理亚型肺腺癌EGFR突变率存在差异,其中腺泡状为主型肺腺癌较非腺泡状为主型肺腺癌的EGFR基因突变发生率高,实性为主型肺腺癌较非实性为主肺腺癌 EGFR突变发生率低,黏液腺癌较非黏液腺癌EGFR基因突变率低。

关键词: 肺腺癌, 表皮生长因子受体, 基因突变

Abstract: Objective: To evaluate the association of the histological subtype of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutation. Methods: A total of 94 patients with resected lung adenocarcinoma in the Department of Thoracic Surgery of China-Japan Friendship Hospital from Ja-nuary 2010 to December 2014 were enrolled in the study. All specimens were tested for EGFR mutation by a company. In the 94 patients, histological subtypes were classified according to the 2011 International Association for the Study of Lung Cancer and American Thoracic Society and European Respiratory Society classification. We compared the association with the histological subtype of lung adenocarcinoma with EGFR mutation frequency by the χ2 test, with SPSS 20.0. Results: The 94 patients of surgically resected lung adenocarcinomas were included in this analysis,of whom,47 were male and 47 female (male ∶female= 1 ∶1) . The median age was 61 (range: 24-79) years, and 48 of the 94 patients were 60 years and above. Regarding the pathological staging, 34 patients were diagnosed as Stage Ⅰ of the disease,17 as Stage Ⅱ,24 as Stage Ⅲ, and 19 as Stage Ⅳ. Among the 51 patients with EGFR mutation, exon 19 mutation was 22, exon 20 mutation was 2, exon 21 mutation was 26, exon 20 and 21 mutation were 1, and the total EGFR mutation rate was 54.3% (51/94). The cases of EGFR gene mutation of acinar predominant lung adenocarcinoma, lepidic predominant lung adenocarcinoma, papillary predominant lung adenocarcinoma, solid predominant lung adenocarcinoma, micropapillary predominant lung adenocarcinoma and mucious adenocarcinoma were 24, 14, 5, 5, 3, and 0, respectively. The rate of EGFR gene mutation of acinar predominant lung adenocarcinoma was higher than that of non-acinar predominant lung adenocarcinom, but there was not statistically significant (66.7% vs. 46.6%, P=0.057). The rate of EGFR gene mutation of solid predominant lung adenocarcinoma was lower than that of non-solid predominant lung adenocarcinom (26.3% vs. 61.3%, P=0.005). The rate of EGFR gene mutation of mucious adenocarcinoma was lower than that of non-mucious adenocarcinom (0 vs. 57.3%, P=0.018).Conclusion: There is heterogeneity of EGFR mutation in lung adenocarcinoma. The presence of lung adenocarcinoma with acinar indicates a higher EGFR mutation rate, while the solid and mucinous component indicates a lower EGFR mutation rate.

Key words: Epidermal growth factor receptor, Lung adenocarcinoma, Mutation

中图分类号: 

  • R655.3
[1] 时云飞,王豪杰,刘卫平,米岚,龙孟平,刘雁飞,赖玉梅,周立新,刁新婷,李向红. 血管免疫母细胞性T细胞淋巴瘤临床与分子病理学特征分析[J]. 北京大学学报(医学版), 2023, 55(3): 521-529.
[2] 朱晓娟,张虹,张爽,李东,李鑫,徐玲,李挺. 人表皮生长因子受体2低表达乳腺癌的临床病理学特征及预后[J]. 北京大学学报(医学版), 2023, 55(2): 243-253.
[3] 王跃,张爽,张虹,梁丽,徐玲,程元甲,段学宁,刘荫华,李挺. 激素受体阳性/人表皮生长因子受体2阴性乳腺癌临床病理特征及预后[J]. 北京大学学报(医学版), 2022, 54(5): 853-862.
[4] 秦彩朋,宋宇轩,丁梦婷,王飞,林佳兴,杨文博,杜依青,李清,刘士军,徐涛. 肾癌免疫治疗疗效评估突变预测模型的建立[J]. 北京大学学报(医学版), 2022, 54(4): 663-668.
[5] 廖栩鹤,王荣福,刘萌,陈雪祺,熊焰,农琳,殷雷,张炳晔,杜毓菁. 18F-FDG PET/CT半定量参数、表皮生长因子受体和间变淋巴瘤激酶基因突变对肺腺癌患者预后评估的价值[J]. 北京大学学报(医学版), 2021, 53(2): 246-254.
[6] 吴君怡,余淼,孙仕晨,樊壮壮,郑静蕾,张刘陶,冯海兰,刘洋,韩冬. 少汗性外胚层发育不良患者EDA基因突变检测及表型分析[J]. 北京大学学报(医学版), 2021, 53(1): 24-33.
[7] 梁学军,宫丽颖,周菲,周德敏,祝静静. 非天然氨基酸定点偶联抗人类表皮生长因子受体2-抗体偶联药物的药理学活性[J]. 北京大学学报(医学版), 2019, 51(5): 797-804.
[8] 尤柱,徐丽莉,李雪芬,张建运,杜菁,孙丽莎. 成釉细胞纤维瘤中BRAF突变基因的检测[J]. 北京大学学报(医学版), 2019, 51(1): 4-5.
[9] 王皓,刘洋,刘浩辰,韩冬,冯海兰. 先天性缺牙患者中BMP2基因突变检测及功能分析[J]. 北京大学学报(医学版), 2019, 51(1): 9-15.
[10] 马晓梅,曹燕珍,姬文莉,赵峰,房新志. 新疆原发性肺腺癌表皮生长因子受体基因突变与临床病理特征分析[J]. 北京大学学报(医学版), 2016, 48(4): 663-666.
[11] 田新霞, 张云岗, 杜娟, 郑杰. 反义表皮生长因子受体cDNA转染对胶质母细胞瘤端粒酶活性的影响[J]. 北京大学学报(医学版), 2005, 37(3): 314-319.
[12] 马彦, 王冬梅, 朱学骏. 一营养不良型大疱表皮松解症家系的基因突变[J]. 北京大学学报(医学版), 2002, 34(2): 171-173.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!